The infliximab multinational psoriatic arthritis controlled trial (IMPACT): Results of radiographic analyses after 1 year - 21/08/11
Doi : 10.1016/j.jaad.2004.10.798
Le texte complet de cet article est disponible en PDF.
Christian Antoni, MD, Department of Medicine, Friedrich-Alexander University, Erlangen, Germany; Desiree van der Heijde, MD, University Hospital Maastricht, Maastricht, Netherlands; Dafna Gladman, MD, Toronto Western Hospital, Toronto, ON, Canada; Arthur Kavanaugh, MD, University of California, San Diego, Division of Rheumatology, Allergy, and Immunology, La Jolla, CA, United States
Le texte complet de cet article est disponible en PDF.| P2802 Dr. Antoni is an investigator and consultant for infliximab at Centocor. Dr. van der Heijde has received research grants and consulting fees or other remuneration from Centocor, Inc. Dr. Gladman received study support from Centocor, Inc. Dr. Kavanaugh has consulted and participated in clinical research for Centocor, Amgen, and Abbott Laboratories. The studies have been funded by research grants from Centocor (IMPACT) or have been done by Centocor (IMPACT 2). |
© 2005
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 52 - N° 3S
P. P197 - mars 2005 Retour au numéro
Article précédent
- The intrarater and interrater reliability of three psoriasis scoring systems (LS-PGA, PASI, and PGA)
- The effect of etanercept therapy on fatigue in patients with moderate to severe psoriasis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?